Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016
- PMID: 29777153
- PMCID: PMC5959930
- DOI: 10.1038/s41598-018-26138-5
Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016
Abstract
This study explores the prevalence of, and factors associated with, likely depression and diabetes distress in adults with type 2 diabetes in a large, national sample. Australian National Diabetes Audit data were analysed from adults with type 2 diabetes attending 50 diabetes centres. The Brief Case find for Depression and Diabetes Distress Score 17 were administered to screen for likely depression and diabetes-related distress, respectively. A total of 2,552 adults with type 2 diabetes participated: (mean ± SD) age was 63 ± 13 years, diabetes duration was 12 ± 10 years, and HbA1c was 8 ± 2%. Twenty-nine percent of patients had likely depression, 7% had high diabetes distress, and 5% had both. Difficulty following dietary recommendations, smoking, forgetting medications, and diabetes distress were all associated with greater odds of depression whereas higher own health rating was associated with lower odds (all p < 0.02). Female gender, increasing HbA1c, insulin use, difficulty following dietary recommendations and depression were all associated with greater odds of diabetes distress & older age, higher own health rating and monitoring blood glucose levels as recommended were associated with lower odds (all p < 0.04). Depression was associated with sub-optimal self-care, while diabetes distress was associated with higher HbA1c and sub-optimal self-care.
Conflict of interest statement
W. Davis reports past participation in advisory boards and/or receiving honoraria from Novo Nordisk and Eli Lilly Australia. S. Andrikopoulos reports past participation in advisory boards and/or receiving honoraria from GlaxoSmithKline Pty Ltd, Novartis Pty Ltd, AstraZeneca Pty Ltd/Bristol-Myers Squibb Australia Pty Ltd, Eli Lilly Australia, Janssen Cilag Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd, Sanofi Aventis Pty Ltd, Novo Nordisk, Servier Laboratories Pty Ltd. J Speight is a member of the Accu-Check Advisory Board (Roche Diabetes Care) and has attended Advisory Board meetings for Medtronic and Janssen. Her research group (The Australian Centre for Behavioural Research in Diabetes) has received honoraria in relation to the above Advisory Board meetings, unrestricted educational grants from Medtronic and Sanofi Diabetes; sponsorship to host or attend educational meetings from Lilly, Medtronic, MSD, Novo Nordisk, Roche Diabetes Care, and Sanofi Diabetes; consultancy income from Abbott Diabetes Care, Astra Zeneca, Roche Diabetes Care, and Sanofi Diabetes. S. Zoungas reports past participation in advisory boards/contract work on behalf of Monash University with AstraZeneca Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd and Novo Nordisk Pty Ltd. S. Zoungas holds a NHMRC senior research fellowship. The remaining authors declare that they have no competing interests.
Figures
References
-
- DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603–1658. doi: 10.1016/S0140-6736(16)31460-X. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
